Indications
Stiglatra is indicated for use in patients with type 2 diabetes aged 18 years and older in addition to diet and exercise to improve glycemic control:
- as monotherapy in patients who are not indicated for the use of metformin due to intolerance or contraindications.
- as a combination therapy with metformin, sulfonylurea derivatives, dipeptidyl peptidase 4 (DPP-4) inhibitors (including in combination with metformin) and insulin preparations in the absence of adequate glycemic control on this therapy.
Reviews
There are no reviews yet